Julia M. Tsuverkalova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia M. Tsuverkalova has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail Vladimirovich Pokrovskii
Belgorod State National Research University
3 shared publications - Vladimir V. Gureev
Belgorod State National Research University
2 shared publications - Anastasia V. Gureeva
Kursk State Medical University 3 K. Marx St. 305041 Kursk Russia
1 shared publication - Anton A. Bolgov
Belgorod State National Research University
1 shared publication - Anton P. Danilenko
Belgorod State National Research University
1 shared publication - Dmitry V. Shcheblykin
Belgorod State National Research University
1 shared publication
Latest Publications
- 11 April 2025
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (3) , 16-21
Агонист имидазолиновых рецепторов I1 – I2 в коррекции проявлений экспериментальной преэклампсии у мышей с мутацией в гене Agouti
Преэклампсия — опасное осложнение беременности, характеризуется эндотелиальной дисфункцией макро- и микрососудистого русла и артериальной гипертензией, что приводит к неблагоприятным последствиям как для матери, так и для плода. Несмотря на существующие методы лекарственного лечения, поиск новых и более эффективных фармакологических веществ остается актуальной задачей. Субстанция С7070 (агонист имидазолиновых рецепторов 1 и 2 типов, 20 мг/кг внутрижелудочно, с 13 по 19 сут гестации) вызывает снижение уровня систолического артериального давления на 18,4 %, до 117,9 ± 1,64 мм рт. ст. (p < 0,05), и диастолического артериального давления — на 26,3 %, до 72,6 ± 1,75 мм рт. ст. (p < 0,05), при экспериментальной преэклампсии у мышей с мутацией в гене Agouti. Отмечено снижение коэффициента эндотелиальной дисфункции с 4,66 ± 0,07 до 1,3 ± 0,03 (p < 0,05) и уровня C-реактивного белка в 2,4 раза (p < 0,05), по сравнению с животными без использования фармакологической поддержки. Кроме того, субстанция С7070 обладает выраженным метаболическим действием, снижая концентрацию глюкозы в крови с 10,3 ± 0,3 до 7,3 ± 0,28 ммоль/л (p < 0,05), концентрацию общего холестерина и триглицеридов — с 3,7 ± 0,12 до 2,7 ± 0,12 ммоль/л (p < 0,05) и с 2,2 ± 0,12 до 1,3 ± 0,09 ммоль/л (p < 0,05), соответственно.
- 11 April 2025
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 88 (3) , 16-21
Агонист имидазолиновых рецепторов I1 – I2 в коррекции проявлений экспериментальной преэклампсии у мышей с мутацией в гене Agouti
Преэклампсия — опасное осложнение беременности, характеризуется эндотелиальной дисфункцией макро- и микрососудистого русла и артериальной гипертензией, что приводит к неблагоприятным последствиям как для матери, так и для плода. Несмотря на существующие методы лекарственного лечения, поиск новых и более эффективных фармакологических веществ остается актуальной задачей. Субстанция С7070 (агонист имидазолиновых рецепторов 1 и 2 типов, 20 мг/кг внутрижелудочно, с 13 по 19 сут гестации) вызывает снижение уровня систолического артериального давления на 18,4 %, до 117,9 ± 1,64 мм рт. ст. (p < 0,05), и диастолического артериального давления — на 26,3 %, до 72,6 ± 1,75 мм рт. ст. (p < 0,05), при экспериментальной преэклампсии у мышей с мутацией в гене Agouti. Отмечено снижение коэффициента эндотелиальной дисфункции с 4,66 ± 0,07 до 1,3 ± 0,03 (p < 0,05) и уровня C-реактивного белка в 2,4 раза (p < 0,05), по сравнению с животными без использования фармакологической поддержки. Кроме того, субстанция С7070 обладает выраженным метаболическим действием, снижая концентрацию глюкозы в крови с 10,3 ± 0,3 до 7,3 ± 0,28 ммоль/л (p < 0,05), концентрацию общего холестерина и триглицеридов — с 3,7 ± 0,12 до 2,7 ± 0,12 ммоль/л (p < 0,05) и с 2,2 ± 0,12 до 1,3 ± 0,09 ммоль/л (p < 0,05), соответственно.
- Open Access
- 22 December 2022
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 8 (4) , 115-139
Endothelial dysfunction: developmental mechanisms and therapeutic strategies
Introduction: Every year the importance of the normal functioning of the endothelial layer of the vascular wall in maintaining the health of the body becomes more and more obvious. The physiological role of the endothelium: The endothelium is a metabolically active organ actively involved in the regulation of hemostasis, modulation of inflammation, maintenance of hemovascular homeostasis, regulation of angiogenesis, vascular tone, and permeability. Risk factors for the development of endothelial dysfunction: Currently, insufficient bioavailability of nitric oxide is considered the most significant risk factor for endothelial dysfunction. Mechanisms of development of endothelial dysfunction: The genesis of endothelial dysfunction is a multifactorial process. Among various complex mechanisms, this review examines oxidative stress, inflammation, hyperglycemia, vitamin D deficiency, dyslipidemia, excess visceral fat, hyperhomocysteinemia, hyperuricemia, as well as primary genetic defect of endotheliocytes, as the most common causes in the population underlying the development of endothelial dysfunction. Markers of endothelial dysfunction in various diseases: This article discusses the main biomarkers of endothelial dysfunction currently used, as well as promising biomarkers in the future for laboratory diagnosis of this pathology. Therapeutic strategies: Therapeutic approaches to the endothelium in order to prevent or reduce a degree of damage to the vascular wall are briefly described. Conclusion: Endothelial dysfunction is a typical pathological process involved in the pathogenesis of many diseases. Thus, pharmacological agents with endothelioprotective properties can provide more therapeutic benefits than a drug without such an effect.
- 22 December 2022
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 8 (4) , 115-139
Open AccessEndothelial dysfunction: developmental mechanisms and therapeutic strategies
Introduction: Every year the importance of the normal functioning of the endothelial layer of the vascular wall in maintaining the health of the body becomes more and more obvious. The physiological role of the endothelium: The endothelium is a metabolically active organ actively involved in the regulation of hemostasis, modulation of inflammation, maintenance of hemovascular homeostasis, regulation of angiogenesis, vascular tone, and permeability. Risk factors for the development of endothelial dysfunction: Currently, insufficient bioavailability of nitric oxide is considered the most significant risk factor for endothelial dysfunction. Mechanisms of development of endothelial dysfunction: The genesis of endothelial dysfunction is a multifactorial process. Among various complex mechanisms, this review examines oxidative stress, inflammation, hyperglycemia, vitamin D deficiency, dyslipidemia, excess visceral fat, hyperhomocysteinemia, hyperuricemia, as well as primary genetic defect of endotheliocytes, as the most common causes in the population underlying the development of endothelial dysfunction. Markers of endothelial dysfunction in various diseases: This article discusses the main biomarkers of endothelial dysfunction currently used, as well as promising biomarkers in the future for laboratory diagnosis of this pathology. Therapeutic strategies: Therapeutic approaches to the endothelium in order to prevent or reduce a degree of damage to the vascular wall are briefly described. Conclusion: Endothelial dysfunction is a typical pathological process involved in the pathogenesis of many diseases. Thus, pharmacological agents with endothelioprotective properties can provide more therapeutic benefits than a drug without such an effect.
- Open Access
- 2 March 2021
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 8 (5) , 304-315-315
CORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY
The aimof the experiment was to determine the effectiveness of the combined use of trimetazidine and a purified micronized flavonoid fraction, as well as their combinations with methyldopa, in comparison with monotherapy with the same drugs in the correction of morphofunctional disorders arising in the conditions of experimental preeclampsia. An integrated/multimethodology approach is the most effective way of treatment for preeclampsia. Therefore, an urgent task of modern pharmacology is to study the effectiveness of new drugs when used in combinations, as well as the drugs included in the standards for treatment.Materials and methods. The study was carried out at the Research Institute of Pharmacology of Living Systems of Belgorod State National Research University. The experiment was performed on 200 female Wistar rats, weighing 250–300 g, in which an ADMA-like model of preeclampsia had been reproduced. To assess the degree of correction of emerging morphological and functional disorders, the following parameters were involved: blood pressure, a coefficient of endothelial dysfunction, microcirculation in the placenta, proteinuria, fluid contents in the greater omentum, morphometric indicators of placental tissues and fetal height and weight parameters.Results. The combined use of trimetazidine (Preductal® MB) 6 mg/kg and a purified micronized flavonoid fraction (Detralex®) 260 mg/kg, as well as their combination with methyldopa (Dopegit®) 86 mg/kg, leads to a more pronounced decrease in the blood pressure, compared with a decrease in the coefficient of endothelial dysfunction by 2.22, 2.19 and 1.94 times, respectively, in relation to “untreated” animals. There was an increase in microcirculation indices in the placenta by 2.35, 2.21 and 2.03 times, respectively. In addition, there was an improvement in morphological parameters in the placenta and fetuses.Conclusion. The results of the study showed a greater effectiveness of the combined use of the studied drugs in experimental preeclampsia compared to their monotherapy. This indicates the prospects for the use of trimetazidine and purified micronized flavonoid fraction in the complex therapy for preeclampsia and the need for further research in this direction.
- 2 March 2021
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 8 (5) , 304-315-315
Open AccessCORRECTION OF MORPHOFUNCTIONAL DISORDERS IN EXPERIMENTAL PREECLAMPSY BY COMBINED USE OF TRIMETAZIDINE AND PURIFIED MICRONIZED FLAVONOID FRACTION AS WELL AS THEIR COMBINATIONS WITH METHYLAMPSY
The aimof the experiment was to determine the effectiveness of the combined use of trimetazidine and a purified micronized flavonoid fraction, as well as their combinations with methyldopa, in comparison with monotherapy with the same drugs in the correction of morphofunctional disorders arising in the conditions of experimental preeclampsia. An integrated/multimethodology approach is the most effective way of treatment for preeclampsia. Therefore, an urgent task of modern pharmacology is to study the effectiveness of new drugs when used in combinations, as well as the drugs included in the standards for treatment.Materials and methods. The study was carried out at the Research Institute of Pharmacology of Living Systems of Belgorod State National Research University. The experiment was performed on 200 female Wistar rats, weighing 250–300 g, in which an ADMA-like model of preeclampsia had been reproduced. To assess the degree of correction of emerging morphological and functional disorders, the following parameters were involved: blood pressure, a coefficient of endothelial dysfunction, microcirculation in the placenta, proteinuria, fluid contents in the greater omentum, morphometric indicators of placental tissues and fetal height and weight parameters.Results. The combined use of trimetazidine (Preductal® MB) 6 mg/kg and a purified micronized flavonoid fraction (Detralex®) 260 mg/kg, as well as their combination with methyldopa (Dopegit®) 86 mg/kg, leads to a more pronounced decrease in the blood pressure, compared with a decrease in the coefficient of endothelial dysfunction by 2.22, 2.19 and 1.94 times, respectively, in relation to “untreated” animals. There was an increase in microcirculation indices in the placenta by 2.35, 2.21 and 2.03 times, respectively. In addition, there was an improvement in morphological parameters in the placenta and fetuses.Conclusion. The results of the study showed a greater effectiveness of the combined use of the studied drugs in experimental preeclampsia compared to their monotherapy. This indicates the prospects for the use of trimetazidine and purified micronized flavonoid fraction in the complex therapy for preeclampsia and the need for further research in this direction.